We have provided experimental results demonstrating that mifepristone, a pharmacological agent previously known as a steroid analogue, promotes secretion of adiponectin both in an in vivo model of HFD-induced obesity and in an in vitro model of 3T3-L1 cells. Here, ADIPOQ is linked to obesity disorder.